Page 46 - Read Online

Page 12 of 13 Yagishita et al. J Cancer Metastasis Treat 2019;5:75 I http://dx.doi.org/10.20517/2394-4722.2019.026

dependent cellular cytotoxic activity. Nat Biotechnol 1999;17:176-80.
17. Kirin K. Poteligent technology. Available from: https://www.kyowakirin.com/biowa/out-licensing/technologies/index.html. [Last accessed
on 6 Nov 2019]
18. GlycoMAb technology. Available from: https://www.roche.ch/en/standorte/schlieren/schlieren_about_glycomab.htm. [Last accessed on 6
Nov 2019]
19. Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical
efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008;26:1789-96.
20. Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, et al. FcgammaR2A and 3A polymorphisms predict clinical outcome of
trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. Ann Oncol 2011;22:1302-7.
21. Hurvitz SA, Betting DJ, Stern HM, Quinaux E, Stinson J, et al. Analysis of Fcgamma receptor IIIa and IIa polymorphisms: lack of
correlation with outcome in trastuzumab-treated breast cancer patients. Clin Cancer Res 2012;18:3478-86.
22. Musolino A, Naldi N, Dieci MV, Zanoni D, Rimanti A, et al. Immunoglobulin G fragment C receptor polymorphisms and efficacy of
preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer. Pharmacogenomics J 2016;16:472-7.
23. Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and
polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8.
24. Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients
with follicular lymphoma. J Clin Oncol 2003;21:3940-7.
25. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, et al. FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP
therapy for diffuse large B-cell lymphoma. Blood 2006;108:2720-5.
26. Carlotti E, Palumbo GA, Oldani E, Tibullo D, Salmoiraghi S, et al. FcgammaRIIIA and FcgammaRIIA polymorphisms do not
predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab. Haematologica
2007;92:1127-30.
27. Mitroviç Z, Aurer I, Radman I, Ajdukovic R, Sertic J, et al. FCgammaRIIIA and FCgammaRIIA polymorphisms are not associated with
response to rituximab and CHOP in patients with diffuse large B-cell lymphoma. Haematologica 2007;92:998-9.
28. Dornan D, Spleiss O, Yeh RF, Duchateau-Nguyen G, Dufour A, et al. Effect of FCGR2A and FCGR3A variants on CLL outcome. Blood
2010;116:4212-22.
29. Zhang W, Wang X, Li J, Duan MH, Zhou DB. Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse
large B-cell lymphoma. Chin Med J (Engl) 2010;123:198-202.
30. Ahlgrimm M, Pfreundschuh M, Kreuz M, Regitz E, Preuss KD, et al. The impact of Fc-gamma receptor polymorphisms in elderly patients
with diffuse large B-cell lymphoma treated with CHOP with or without rituximab. Blood 2011;118:4657-62.
31. Fabisiewicz A, Paszkiewicz-Kozik E, Osowiecki M, Walewski J, Siedlecki JA. FcgammaRIIA and FcgammaRIIIA polymorphisms do not
influence survival and response to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy in patients
with diffuse large B-cell lymphoma. Leuk Lymphoma 2011;52:1604-6.
32. Prochazka V, Papajik T, Gazdova J, Divoka M, Rozmanova S, et al. FcγRIIIA receptor genotype does not influence an outcome in patients
with follicular lymphoma treated with risk-adapted immunochemotherapy. Neoplasma 2011;58:263-70.
33. Ghesquieres H, Cartron G, Seymour JF, Delfau-Larue MH, Offner F, et al. Clinical outcome of patients with follicular lymphoma receiving
chemoimmunotherapy in the PRIMA study is not affected by FCGR3A and FCGR2A polymorphisms. Blood 2012;120:2650-7.
34. Persky DO, Dornan D, Goldman BH, Braziel RM, Fisher RI, et al. Fc gamma receptor 3a genotype predicts overall survival in follicular
lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone.
Haematologica 2012;97:937-42.
35. Varoczy L, Zilahi E, Gyetvai A, Kajtar B, Gergely L, et al. Fc-gamma-receptor IIIa polymorphism and gene expression profile do not predict
the prognosis in diffuse large B-cell lymphoma treated with R-CHOP protocol. Pathol Oncol Res 2012;18:43-8.
36. Ghesquieres H, Larrabee BR, Haioun C, Link BK, Verney A, et al. FCGR3A/2A polymorphisms and diffuse large B-cell lymphoma outcome
treated with immunochemotherapy: a meta-analysis on 1134 patients from two prospective cohorts. Hematol Oncol 2017;35:447-55.
37. Liu F, Ding H, Jin X, Ding N, Deng L, He Y, Zhu J, Song Y. FCGR3A 158V/F polymorphism and response to frontline R-CHOP therapy in
diffuse large B-cell lymphoma. DNA Cell Biol 2014;33:616-23.
38. Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a
comprehensive review of registration trials and future considerations. J Immunother Cancer 2018;6:8.
39. Havel JJ, Chowell D, Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer
2019;19:133-50.
40. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, et al. Signatures of mutational processes in human cancer. Nature
2013;500:415-21.
41. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N
Engl J Med 2014;371:2189-99.
42. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, et al. Cancer immunology. Mutational landscape determines sensitivity to
PD-1 blockade in non-small cell lung cancer. Science 2015;348:124-8.
43. Van Allen EM, Miao D, Schilling B, Shukla SA, Blank C, et al. Genomic correlates of response to CTLA-4 blockade in metastatic
melanoma. Science 2015;350:207-11.
44. Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational Burden and response rate to PD-1 inhibition. N Engl J Med 2017;377:2500-1.
45. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med
2015;372:2509-20.
46. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Science 2017;357:409-13.